The following article appeared online today on InsideHealthPolicy.com, a subscription service. We are sharing the full article here.
Posted: May 16, 2013
Rare Disease Group Pushes Endpoint Discussion In FDASIA Guide
Without key changes to FDA's consideration of surrogate and intermediate endpoints, drugs in the pipeline to treat muscular dystrophy will not make it to…
Continue Mary-Lou Weisman
Mary-Lou Weisman, author of Intensive Care and founder of Fund for Pete's Sake. To learn more or to read Mary-Lou's blog, visit …
Guest post by Ivy Scherbarth. Ivy is a Colorado/Wyoming FACES Coordinator for PPMD. Follow Ivy at her blog, Living Duchenne.
…
Continue2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service